<DOC>
	<DOCNO>NCT01655381</DOCNO>
	<brief_summary>This open-label , single arm , multicenter long-term extension study evaluate safety efficacy tocilizumab ( RoActemra/Actemra ) participant moderate severe rheumatoid arthritis complete 104-week WA19926 core study . Eligible participant receive tocilizumab 8 mg/kg intravenously every 4 week 104 week .</brief_summary>
	<brief_title>A Long-Term Extension Study WA19926 Safety Tocilizumab ( RoActemra/Actemra ) Participants With Early Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Participants complete last WA19926 core study visit ( Week 104 ) may benefit study drug treatment , baseline later remission DAS28 Week 104 WA19926 , accord Investigator 's assessment No current recent adverse event laboratory find prevent use study drug dose tocilizumab 8 mg/kg baseline visit Women childbearing potential must agree use adequate contraception define protocol 3 month treatment Pregnant females Participants withdrawn prematurely WA19926 core study reason Treatment investigational agent celldepleting therapy since last administration study drug WA19926 Treatment antitumor necrosis factor ( TNF ) antiinterleukin ( IL ) 1 agent , Tcell costimulation modulator since last administration study drug WA19926 Immunization live/attenuated vaccine since last administration study drug WA19926 Diagnosis since last WA19926 visit ( Week 104 ) rheumatic autoimmune disease rheumatoid arthritis Diagnosis since last WA19926 visit ( Week 104 ) inflammatory joint disease rheumatoid arthritis History severe allergic anaphylactic reaction humanize murine monoclonal antibody , include tocilizumab excipients Evidence severe uncontrolled concomitant disease disorder Known active history recurrent infection Active tuberculosis require treatment previous 3 year History alcohol , drug chemical abuse since inclusion WA19926 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>